BlackRock® Canada Announces Final June Cash Distributions for the iShares® Premium Money Market ETF
TORONTO, June 24, 2025 (GLOBE NEWSWIRE) -- BlackRock Asset Management Canada Limited ('BlackRock Canada'), an indirect, wholly-owned subsidiary of BlackRock, Inc. (NYSE: BLK), today announced the final June 2025 cash distributions for iShares Premium Money Market ETF. Unitholders of record on June 25, 2025 will receive cash distributions payable on June 30, 2025.
Details regarding the final 'per unit' distribution amounts are as follows:
Fund Name
Fund Ticker
Cash Distribution Per Unit
iShares Premium Money Market ETF
CMR
$0.129
Further information on the iShares ETFs can be found at http://www.blackrock.com/ca.
About BlackRockBlackRock's purpose is to help more and more people experience financial well-being. As a fiduciary to investors and a leading provider of financial technology, we help millions of people build savings that serve them throughout their lives by making investing easier and more affordable. For additional information on BlackRock, please visit www.blackrock.com/corporate | Twitter: @BlackRockCA
About iShares ETFsiShares unlocks opportunity across markets to meet the evolving needs of investors. With more than twenty years of experience, a global line-up of 1500+ exchange traded funds (ETFs) and US$4.3 trillion in assets under management as of March 31, 2025, iShares continues to drive progress for the financial industry. iShares funds are powered by the expert portfolio and risk management of BlackRock.
iShares® ETFs are managed by BlackRock Canada.
Commissions, trailing commissions, management fees and expenses all may be associated with investing in iShares ETFs. Please read the relevant prospectus before investing. The funds are not guaranteed, their values change frequently and past performance may not be repeated. Tax, investment and all other decisions should be made, as appropriate, only with guidance from a qualified professional.
Contact for Media:Sydney PunchardEmail: Sydney.Punchard@blackrock.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
39 minutes ago
- Business Wire
Takeda Announces New Assignments of Directors
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting, following the 149th Annual Meeting of Shareholders, held in Osaka today. Takeda's Board of Directors has 11 members serving as external directors out of a total of 14 members, helping to ensure transparency and objectivity. An external director will continue to chair the Board of Directors. The Audit and Supervisory Committee, the Nomination Committee and the Compensation Committee will be composed solely of external directors including their chairs. Takeda highly values strong, independent governance and its Board of Directors helps to ensure that all decisions and actions are in the best interests of global stakeholders and aligned with the company's values. This robust corporate governance model has been, and will continue to be, critical to Takeda's success. Details of the new assignments are as follows: 1. New Assignment of Directors Who Are Not Audit and Supervisory Committee Members (Effective June 25, 2025) 2. Directors Who Are Audit and Supervisory Committee Members 3. New Assignment of Nomination Committee and Compensation Committee Members (Effective June 25, 2025) Nomination committee: Masami Iijima (Chairperson), Steven Gillis, Emiko Higashi, Michel Orsinger, Jean-Luc Butel and Yoshiaki Fujimori (Observer: Christophe Weber) Compensation committee: Emiko Higashi (Chairperson), John Maraganore, Michel Orsinger, Miki Tsusaka and Kimberly A. Reed About Takeda Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit Important Notice For the purposes of this notice, 'press release' means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ('Takeda') regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, 'Takeda' is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words 'we', 'us' and 'our' are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies. Forward-Looking Statements This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as 'targets', 'plans', 'believes', 'hopes', 'continues', 'expects', 'aims', 'intends', 'ensures', 'will', 'may', 'should', 'would', 'could', 'anticipates', 'estimates', 'projects', 'forecasts', 'outlook' or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda's global business, including general economic conditions in Japan and the United States and with respect to international trade relations; competitive pressures and developments; changes to applicable laws and regulations, including tax, tariff and other trade-related rules; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals; the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits; and other factors identified in Takeda's most recent Annual Report on Form 20-F and Takeda's other reports filed with the U.S. Securities and Exchange Commission, available on Takeda's website at: or at Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda's future results.
Business Insider
2 hours ago
- Business Insider
Canaccord Genuity Sticks to Their Buy Rating for Bank Of Montreal (BMO)
Canaccord Genuity analyst Matthew Lee maintained a Buy rating on Bank Of Montreal (BMO – Research Report) today and set a price target of C$166.00. The company's shares closed today at $106.73. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Lee covers the Industrials sector, focusing on stocks such as CAE, Air Canada, and Diversified Royalty Corp. According to TipRanks, Lee has an average return of 13.1% and a 65.05% success rate on recommended stocks. In addition to Canaccord Genuity, Bank Of Montreal also received a Buy from RBC Capital's Darko Mihelic in a report issued on June 9. However, on the same day, Barclays downgraded Bank Of Montreal (NYSE: BMO) to a Hold. BMO market cap is currently $76.08B and has a P/E ratio of 13.59.
Business Insider
2 hours ago
- Business Insider
BlackRock Stock (BLK) Gets a Boost from Its New Texas ETF
BlackRock (BLK) announced the launch of a new exchange-traded fund (ETF) that is focused on businesses in Texas. This fund, named iShares Texas Equity ETF (TEXN), will invest in companies that are headquartered in the state. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter BlackRock created the new Texas ETF as more corporations have moved their operations to the state, or are expanding their presence in it. A few notable examples include Tesla (TLSA), Chevron (CVX), Charles Schwab (SCHW), Oracle (ORCL), Hewlett Packard Enterprise (HPE), and Caterpillar (CAT). Interest in moving headquarters to Texas has grown due to the state's favorable tax laws. That's resulted in many businesses shifting operations out of California and other states with stricter tax laws. This has sparked concern from residents of these states that lost tax revenue will negatively affect them. BlackRock's Investments In Texas BlackRock's Texas ETF fund makes sense as the firm has $380 billion in assets connected to companies in the state. Included in that is $115 billion in the state's oil and gas industry. Its huge interest in Texas allows it to offer an ETF that already has strong ties to the area. BLK stock was up 1.43% as of Tuesday afternoon, extending a 24.16% 12-month rally. On the flip side of that, shares are down 1.35% year-to-date. The stock also received a reiterated Buy rating and $1,154 price target from five-star TD Cowen analyst William Katz. Is BlackRock Stock a Buy, Sell, or Hold? Turning to Wall Street, the analysts' consensus rating for BlackRock is Moderate Buy, based on 11 Buy and two Hold ratings over the past 12 months. With that comes an average BLK stock price target of $1,058.85, representing a potential 5.68% upside for the shares.
